



























































Table	1.	Description	of	the	GWASs	summary	statistics		Neurodegenerative	disease	 PMID	 Cases	 Controls	 Cohorts	Parkinson’s	disease	(PD)	 25064009		 13,708	 95,282	 15	
Alzheimer’s	disease	(AD)	 24162737	 17,008	 37,154	 19	Amyotrophic	lateral	sclerosis	(ALS)	 24256812	 7,177	 8,393	 8	Multiple	sclerosis	(MS)	 21833088		 9,772	 17,376	 23	
	
		
Supplementary	files:	
	
Supplementary	Table	1.	Annotation	enrichment	results.	Red	cells	mark	enrichment	that	survived	Bonferroni	correction.		
	
Supplementary	Table	2.	Overlap	among	chromatin	accessibility	annotations	for	immune	cells.	The	main	diagonal	shows	genome	coverage	(base	pairs)	for	that	cell	type.	The	upper	off-diagonal	shows	the	overlap	coverage	(base	pairs)	for	that	cell-type-pair.	The	lower	off-diagonal	shows	the	proportion	of	overlap	coverage	for	that	cell-type	pair.	
	
Supplementary	Table	3.	[a]	Ingenuity	Pathway	Analysis	(IPA)	results	for	canonical	pathways.	Red	cells	mark	enrichment	that	survived	Bonferroni	correction.	[b]	Ingenuity	Pathway	Analysis	(IPA)	results	for	cancer-related	functions.	Red	cells	mark	enrichment	that	survived	Bonferroni	correction.		[c]	enrichr	KEGG	pathway	results.	Multiplication	of	the	p-value	computed	using	the	Fisher	exact	test	with	the	z-score	of	the	deviation	from	the	expected	rank	as	described	in	the	enrichr	paper.38	
